- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01099774
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
April 9, 2019 updated by: Allergan
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
597
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Newport Beach, California, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has ocular hypertension or glaucoma in both eyes
- Requires IOP-lowering therapy in each eye
Exclusion Criteria:
- Active or recurrent eye disease that would interfere with interpretation of study data in either eye
- History of any eye surgery or laser in either eye within 6 months
- Required chronic use of other eye medications during the study
- Anticipated wearing of contact lenses during the study.
- Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bimatoprost 0.03% Formulation B Ophthalmic Solution
|
One drop administered in each eye, every evening, for 12 weeks
|
Active Comparator: Bimatoprost 0.03% Ophthalmic Solution
|
One drop administered in each eye, every evening, for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12
Time Frame: Baseline, Week 12
|
Change from baseline in worse eye IOP at Week 12 .
IOP is a measurement of fluid pressure inside the eye.
IOP measurements in the worse eye were evaluated at hours 0, 2, and 8.
A negative number change from baseline indicated a reduction in IOP, and a positive number change from baseline indicated an increase in IOP.
|
Baseline, Week 12
|
Average Eye IOP at Week 12
Time Frame: Baseline, Week 12
|
Average Eye IOP at Week 12 .
IOP is a measurement of fluid pressure inside the eye.
IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
Baseline data are included for reference only.
|
Baseline, Week 12
|
Average Eye IOP at Week 6
Time Frame: Week 6
|
Average Eye IOP at Week 6 .
IOP is a measurement of fluid pressure inside the eye.
IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
|
Week 6
|
Average Eye IOP at Week 2
Time Frame: Week 2
|
Average Eye IOP at Week 2 .
IOP is a measurement of fluid pressure inside the eye.
IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
|
Week 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2010
Primary Completion (Actual)
April 29, 2011
Study Completion (Actual)
April 29, 2011
Study Registration Dates
First Submitted
April 6, 2010
First Submitted That Met QC Criteria
April 6, 2010
First Posted (Estimate)
April 8, 2010
Study Record Updates
Last Update Posted (Actual)
April 17, 2019
Last Update Submitted That Met QC Criteria
April 9, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 192024-048
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on Bimatoprost 0.03% Formulation B Ophthalmic Solution
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedIdiopathic Eyelash HypotrichosisRussian Federation, Sweden, United States, United Kingdom
-
AllerganCompletedEyelash HypotrichosisUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedHypotrichosisUnited States
-
AllerganCompletedLong-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionOcular Hypertension | GlaucomaSpain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
-
Tulane UniversityAllerganCompleted
-
Gian Sagar Medical College and HospitalWithdrawnVitiligo | Repigmentation
-
AllerganCompletedOcular Hypertension | Primary Open-Angle GlaucomaUnited States
-
AllerganCompletedAlopecia Areata | Eyelash HypotrichosisUnited States, Brazil